This is very promising, allowing drugs to get to patients faster and costing pharma companies a little less. But getting to market faster only increases the NPV of the drug by as much as IRA would allow. Now what the industry and FDA need to do is to speed up the process of getting drugs into man faster to catch up with China.
Real-time clinical trials could fundamentally transform the clinical trial landscape.